Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Phase 3 trial of ataluren commences

PTC Therapeutics, Inc. (PTC) today announced the initiation of a Phase 3 trial of ataluren (formerly PTC124(R)), an investigational protein restoration therapy in patients with nonsense mutation cystic fibrosis (nmCF).

11 Sep 2009

A non-invasive test for cystic fibrosis is the goal of University Of Arizona researchers

Researchers from The University of Arizona Colleges of Pharmacy and Medicine are teaming up to try to invent a novel non-invasive lung test for cystic fibrosis sufferers.

10 Sep 2009

Inspire Pharmaceuticals to increase production of azithromycin ophthalmic solution

Inspire Pharmaceuticals, Inc. announced today that it has been communicating with the U.S. Food and Drug Administration (FDA) and is increasing its production of AzaSite® (azithromycin ophthalmic solution) 1% in response to the manufacturing supply shortage of erythromycin ophthalmic ointment (0.5%).

10 Sep 2009

Inspire Pharmaceuticals wins award for its denufosol tetrasodium program

Inspire Pharmaceuticals, Inc. announced today it received the North Carolina Health & Life Sciences Award in the category of “Breakthrough Research” for its denufosol tetrasodium program for cystic fibrosis (CF).

9 Sep 2009

Nanoemulsion-based adjuvant increases immunity and cross protection against influenza

NanoBio Corp. announced today that data from a large ferret study indicates that its intranasal, nanoemulsion-based adjuvant elicits robust immunity and cross protection against influenza using 1/15th of the standard antigen dose, without evidence of toxicity or tolerability concerns.

9 Sep 2009

Genetic risk factor involved in cystic fibrosis discovered

Researchers at the University of North Carolina at Chapel Hill have discovered a genetic risk factor for severe liver disease in people with cystic fibrosis. Those who carry a particular variant of the SERPINA1 gene (also known as alpha-1-antitrypsin or alpha-1-antiprotease) are five times more likely to develop cirrhosis and other liver complications than patients who carry the normal version of the gene.

9 Sep 2009

FDA approves new xTAG Cystic Fibrosis 39 Kit v2 from Luminex

Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed solutions, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a new cystic fibrosis (CF) test: the xTAG® Cystic Fibrosis 39 Kit v2.

From Thermo Fisher Scientific Inc. 4 Sep 2009

New treatment for vaso-occlusive crisis in sickle cell patients

GlycoMimetics, Inc. (GMI), a clinical-stage biotechnology company that is developing a new class of glycobiology-based therapies for a broad range of indications, today announced that a pilot study of the company’s lead candidate, GMI-1070, is underway in sickle cell patients. The first patients in this pilot study were treated at Children’s Hospital & Research Center Oakland in California.

4 Sep 2009

Children's Hospital Oakland converts to Masimo Rainbow SET Pulse CO-Oximetry technology

Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that Children's Hospital & Research Center Oakland has completed its system-wide conversions to Masimo Rainbow SET Pulse CO-Oximetry technology.

2 Sep 2009

Researchers demystify polar body analysis reproduction technique

Three out of ten women who undergo polar body diagnosis go on to have a child. The extensive technique of polar body analysis (PBA) is described by researchers in reproductive medicine at Lübeck in an article in the current edition of Deutsches Ärtzeblatt International, in which they present three successful cases and one failure.

31 Aug 2009

Morria Biopharmaceuticals receives approval to commence its Phase II clinical trial on MRX6

Morria Biopharmaceuticals Plc, a biopharmaceutical company focusing on novel, non-steroidal anti-inflammatory drugs, announced today that it has received written approval to commence its Phase II clinical trial on its leading topical Multi-Functional Anti Inflammatory Drug (MFAID) MRX6.

26 Aug 2009

Research study reveals that mortality remains high in patients with pulmonary arterial hypertension

Mortality remains high among patients with pulmonary arterial hypertension awaiting lung transplant, despite changes to the allocation system that were designed to reduce mortality and increase the equitable distribution of donor organs, according to new research out of University of California San Francisco.

24 Aug 2009

Scientists to discuss effective treatments for serious diseases at Functional Genomics/Chemical Biology conference

A cure for cystic fibrosis, HIV-fighting 'Trojan horses', new pharmaceuticals from the ocean. Chemical biologists use new and innovative approaches to discover medications of the future. On 24 August, some of the field's most prominent researchers will attend an international conference in Gothenburg, Sweden.

24 Aug 2009

Innovotech reports year-on-year revenue increase for second-quarter 2009

Innovotech Inc. (TSX VENTURE:IOT) today announced its unaudited financial and operational results for the three and six month periods ended June 30, 2009.

21 Aug 2009

Novel genome-analysis strategy to speed search for gene-disease links

University of Washington (UW) researchers have successfully developed a novel genome-analysis strategy for more rapid, lower cost discovery of possible gene-disease links. By saving time and lowering expenses, the approach makes it feasible for scientists to search for disease-causing genes in people with the same inherited disorder but without any family ties to each other.

18 Aug 2009

Secretary Sebelius announces Senate confirmation of Dr. Francis Collins as Director of NIH

HHS Secretary Kathleen Sebelius announced today that the United States Senate unanimously confirmed Dr. Francis Collins as the next Director of the National Institutes of Health.

10 Aug 2009

Aradigm receives orphan drug designation for inhaled liposomal ciprofloxacin to treat cystic fibrosis in Europe

Aradigm Corporation (OTCBB:ARDM) has announced that the European Medicines Agency (EMEA) granted Orphan Drug Designation to the Company’s inhaled liposomal ciprofloxacin drug product candidate for the treatment of lung infections associated with cystic fibrosis (“CF”).

6 Aug 2009

Discovery of potential treatment for spinal muscular atrophy

Spinal Muscular Atrophy is the second-leading cause of infant mortality in the world. Ravindra Singh, associate professor in biomedical sciences at Iowa State University's College of Veterinary Medicine, would like to see Spinal Muscular Atrophy lose its high ranking and even slide off the list altogether.

28 Jul 2009

Miglustat shows promise for cystic fibrosis

Miglustat is a drug currently under phase 2 clinical trials on patients suffering from cystic fibrosis (1). Its potential for treating the disease was discovered in 2006 thanks to the work of Frédéric Becq's team at the Institute of Cell Physiology and Biology (CNRS/Université de Poitiers), funded by the associations Vaincre la Mucoviscidose, MucoVie66, La Pierre Le Bigaut and ABCF2.

21 Jul 2009

Cystic fibrosis medicines that help to break down mucus in the lungs may carry an unexpected long-term benefit

Cystic fibrosis medicines that help to break down mucus in the lungs may carry an unexpected long-term benefit, a study suggests.

16 Jul 2009

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Phase 3 trial of ataluren commences

A non-invasive test for cystic fibrosis is the goal of University Of Arizona researchers

Inspire Pharmaceuticals to increase production of azithromycin ophthalmic solution

Inspire Pharmaceuticals wins award for its denufosol tetrasodium program

Nanoemulsion-based adjuvant increases immunity and cross protection against influenza

Genetic risk factor involved in cystic fibrosis discovered

FDA approves new xTAG Cystic Fibrosis 39 Kit v2 from Luminex

New treatment for vaso-occlusive crisis in sickle cell patients

Children's Hospital Oakland converts to Masimo Rainbow SET Pulse CO-Oximetry technology

Researchers demystify polar body analysis reproduction technique

Morria Biopharmaceuticals receives approval to commence its Phase II clinical trial on MRX6

Research study reveals that mortality remains high in patients with pulmonary arterial hypertension

Scientists to discuss effective treatments for serious diseases at Functional Genomics/Chemical Biology conference

Innovotech reports year-on-year revenue increase for second-quarter 2009

Novel genome-analysis strategy to speed search for gene-disease links

Secretary Sebelius announces Senate confirmation of Dr. Francis Collins as Director of NIH

Aradigm receives orphan drug designation for inhaled liposomal ciprofloxacin to treat cystic fibrosis in Europe

Discovery of potential treatment for spinal muscular atrophy

Miglustat shows promise for cystic fibrosis

Cystic fibrosis medicines that help to break down mucus in the lungs may carry an unexpected long-term benefit

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in